Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?

Core Viewpoint - Adma Biologics has experienced a significant decline in share price, losing approximately 45.4% over the past month, raising questions about its future performance leading up to the next earnings release [1] Financial Performance - For Q4 2025, Adma Biologics reported adjusted earnings per share (EPS) of 21 cents, a 14% increase year-over-year from 14 cents [2] - Reported EPS was 20 cents, down from 46 cents in the same quarter last year [2] - Revenues reached $139.2 million, reflecting an 18% year-over-year increase [3] Product Performance - Asceniv, the lead product, significantly contributed to revenue growth, with sales climbing 51% year-over-year to $362.5 million due to strong demand and prescriber adoption [9] - The company’s revenue for 2025 was $510.2 million, a 20% increase from 2024, driven primarily by Asceniv sales [9] Cost and Margin Improvements - Gross margin improved to 63.8% from 54%, attributed to a favorable mix of higher-margin immunoglobulin sales and operational efficiencies [7] - Research & Development expenses rose to $1.4 million from $0.4 million in the previous year, while selling, general, and administrative expenses increased by 0.84% to $23.5 million [7] Future Guidance - For 2026, Adma Biologics expects revenues to exceed $635 million and net income to surpass $255 million, with continued growth in higher-margin IVIG products [11] - Management forecasts revenues to exceed $775 million in 2027 and over $1.1 billion by 2029, with adjusted EBITDA of at least $700 million [14] Supply Chain and Production Enhancements - The company has integrated yield-enhanced production into routine operations, which is expected to support gross margin expansion and earnings growth [12] - New agreements with third-party suppliers provide access to over 280 plasma collection centers, enhancing long-term supply outlook for Asceniv [13] Pipeline Development - Adma Biologics is advancing SG-001, a hyperimmune globulin targeting S. pneumonia, with potential peak annual sales estimated between $300 million and $500 million [15]